Shandong Huabo Kaisheng Biotechnology, a wholly-owned subsidiary of Guangdong Teyankang Pharmaceutical, has had its baricitinib tablets selected in the 12th National Centralized Drug Procurement. The drug specification is 2 mg, 28 tablets per box, indicated for rheumatoid arthritis. The company stated that during the procurement cycle, medical institutions will prioritize the use of selected products. Following the signing and implementation of procurement contracts, this will facilitate volume sales and market expansion, enhance brand influence, and have a positive impact on future operating performance. However, there remains uncertainty regarding subsequent matters such as the signing of procurement agreements and the impact on company performance.
Guangdong Taienkang Pharmaceutical Co. LtdBaricitinib tablets selected in national procurement, ensuring prioritized use and volume sales.
Wholly-owned subsidiary's product selected, facilitating volume sales and market expansion.
